A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents.

Trial Profile

A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms DELTA
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 12 Jun 2018 This trial has been completed in Germany (end date: 2018-05-16)
    • 24 May 2018 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top